Cell Samples From Patients With Leukemia
Kata kunci
Abstrak
Deskripsi
OBJECTIVES:
- Demonstrate the capability of primary human leukemia samples to survive and proliferate in the zebrafish embryo.
- Confirm the anti-proliferative or toxic effects of known chemotherapeutics on the transplanted cells in vivo.
- Evaluate the effect of novel anticancer drugs and/or their combinations on individual samples.
OUTLINE: This is a multicenter study.
Cryopreserved specimens are injected into the yolk sac of zebrafish embryos under anesthesia. After 1 hour of recovery at 28° C, embryos are maintained at 38° C and screened for fluorescence at the injection site. Within 48 hours post-injection, some embryos are treated with various chemotherapeutic drugs or dimethyl sulfoxide and incubated in protease solution. Proliferation of leukemia cells are monitored by live-cell microscopy. Cells with or without drug treatment are then extracted at 24 and 72 hours post-injection. Leukemia cells are counted and tested with imatinib mesylate, all-trans retinoic acid (tretinoin), cytosine arabinose, and known bioactive chemical compounds from promising drug families, such as tyrosine kinase inhibitors, antiapoptotic agents, channel modulators, and prostaglandin agonists.
tanggal
| Terakhir Diverifikasi: | 04/30/2016 |
| Pertama Dikirim: | 07/13/2011 |
| Perkiraan Pendaftaran Telah Dikirim: | 07/13/2011 |
| Pertama Diposting: | 07/14/2011 |
| Pembaruan Terakhir Dikirim: | 05/16/2016 |
| Pembaruan Terakhir Diposting: | 05/18/2016 |
| Tanggal Mulai Studi Sebenarnya: | 06/30/2011 |
| Perkiraan Tanggal Penyelesaian Utama: | 04/30/2016 |
Kondisi atau penyakit
Intervensi / pengobatan
Drug: in vitro sensitivity-directed chemotherapy
Other: cell proliferation assay
Other: fluorescence activated cell sorting
Other: laboratory biomarker analysis
Other: microscopy
Tahap
Kriteria kelayakan
| Jenis Kelamin yang Layak untuk Belajar | All |
| Metode pengambilan sampel | Non-Probability Sample |
| Menerima Relawan Sehat | Iya |
| Kriteria | DISEASE CHARACTERISTICS: - Samples of blood and tissue cells from patients diagnosed with myeloid disease including the following subtypes: - Chronic phase chronic myeloid leukemia (CML), to complement initial studies in the K562 CML cell line - Acute promyelocytic leukemia (APL), to complement initial studies in the NB4 APL cell line - Acute myeloid leukemia (AML) expressing the t(8;21)(q22;q22) translocation, which occurs in approximately 12% of pediatric AML and is associated with good prognosis - AML expressing 5q- or monosomy 7, associated with a poor prognosis - AML expressing the fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), associated with a poor prognosis PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified |
Hasil
Ukuran Hasil Utama
1. Primary human leukemia samples capable to survive and proliferate in the zebrafish embryo [undefined]
2. In vivo confirmation of anti-proliferative or toxic effects of known chemotherapeutic agents on the transplanted cells [undefined]
3. Effects of novel anticancer drugs and/or their combinations on individual samples [undefined]
